The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
American Society of Clinical Oncology Clinical Practice Guidelines: The Role of Bisphosphonates in Multiple Myeloma
Abstract
PURPOSE: To determine clinical practice guidelines for the use of bisphosphonates in the prevention and treatment of lytic bone disease in multiple myeloma and to determine their respective role relative to other conventional therapies for this condition. METHODS: An expert multidisciplinary Panel reviewed pertinent information from the published literature through January 2002. Values for levels of evidence and grade of recommendation were assigned by expert reviewers and approved by the Panel. Expert consensus was used if there were insufficient published data. The Panel addressed which patients to treat and when to treat them in the course of their disease. Additionally, specific drug delivery issues, duration of therapy, initiation of treatment and management of treatment of lytic bone disease was reviewed and compared with other forms of therapy for lytic bone lesions. Finally, the Panel discussed patient and physician expectations associated with this therapy for bony metastases, as well as public policy implications related to the use of bisphosphonates. The guidelines underwent external review by selected physicians, by the Health Services Research Committee members, and by the ASCO Board of Directors. RESULTS: The available evidence involving randomized controlled trials is modest but supports that oral clodronate, intravenous pamidronate, and intravenous zoledronic acid are superior to placebo in reducing skeletal complications. A reduction in vertebral fractures has consistently been seen across all studies. No agent has shown a definitive survival benefit. Intravenous zoledronic acid has recently been shown to be as effective as intravenous pamidronate. Because there are no direct comparisons between clodronate and pamidronate or zoledronic acid, the superiority of one agent cannot be definitively established. However, the panel recommends only intravenous pamidronate or zoledronic acid in light of the use of the time to first skeletal event as the primary end point and more complete assessment of bony complications in studies evaluating it. Additionally, clodronate is not available in the United States. The choice between pamidronate and zoledronic acid will depend on choosing between the higher drug cost of zoledronic acid, with its shorter, more convenient infusion time (15 minutes), versus the less expensive drug, pamidronate, with its longer infusion time (2 hours). CONCLUSION: Bisphosphonates provide a meaningful supportive benefit to multiple myeloma patients with lytic bone disease. However, further research on bisphosphonates is warranted, including the following: (1) when to start and stop therapy, (2) how to integrate their use with other treatments for lytic bone disease, (3) how to evaluate their role in myeloma patients without lytic bone involvement, (4) how to distinguish between symptomatic and asymptomatic bony events, and (5) how to better determine their cost-benefit consequence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Beahrs, O. H., & Henson, D. E. (1992) · Medical Entomology and Zoology · Cited by 2,460
Effect of Risedronate on the Risk of Hip Fracture in Elderly Women
McClung, M. R., Geusens, P., Miller, P. D., Zippel, H., Bensen, W. G., Roux, C., Adami, S., Fogelman, I., Diamond, T., Eastell, R., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102013440503 · Cited by 1,918
Measuring the quality of life of cancer patients
Spitzer, W. O., Dobson, A. J., Hall, J., Chesterman, E., Levi, J., Shepherd, R., Battista, R. N., & Catchlove, B. R. (1981) · Journal of Chronic Diseases · doi:10.1016/0021-9681(81)90058-8 · Cited by 1,528
Rules of Evidence and Clinical Recommendations on the Use of Antithrombotic Agents
Sackett, D. L. (1989) · Chest · doi:10.1378/chest.95.2_supplement.2s · Cited by 1,368
Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma
Berenson, J. R., Lichtenstein, A., Porter, L., Dimopoulos, M. A., Bordoni, R., George, S., Lipton, A., Keller, A., Ballester, O., Kovacs, M. J., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602223340802 · Cited by 1,081
Self-citationHortobagyi, G. N., Theriault, R. L., Porter, L., Blayney, D., Lipton, A., Sinoff, C., Wheeler, H., Simeone, J. F., Seaman, J., Knight, R. D., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199612123352401 · Cited by 1,026
Self-citationBisphosphonates: Mechanisms of Action
Fleisch, H. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.1.0325 · Cited by 1,019
Rosen, L. S., Gordon, D., Kaminski, M., Howell, A., Belch, A. R., Mackey, J. R., Apffelstaedt, J., Hussein, M., Coleman, R. E., Reitsma, D. J., et al. (2001) · PubMed · Cited by 896
Major, P., Lortholary, A., Hon, J., Abdi, E., Mills, G., Menssen, H. D., Yunus, F., Bell, R., Body, J., Quebe-Fehling, E., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.558 · Cited by 858
Multiple myeloma; a review of 26 cases.
Harnagel, E. E., Kleinberg, I., Kahlstrom, S. C., & Rhudy, F. V. (1957) · PubMed · Cited by 682
Berenson, J. R., Lichtenstein, A., Porter, L., Dimopoulos, M. A., Bordoni, R., George, S., Lipton, A., Keller, A., Ballester, O., Kovacs, M., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.593 · Cited by 648
Self-citationTreatment of Postmenopausal Osteoporosis
Eastell, R. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803123381107 · Cited by 615
Monoclonal gammopathy of undetermined significance
Kyle, R. A. (1978) · The American Journal of Medicine · doi:10.1016/0002-9343(78)90522-3 · Cited by 607
Self-citationPaterson, A. H., Powles, T. J., Kanis, J. A., McCloskey, E., Hanson, J., & Ashley, S. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.1.59 · Cited by 557
Collapsing Focal Segmental Glomerulosclerosis Following Treatment with High-Dose Pamidronate
MARKOWITZ, G. S., APPEL, G. B., FINE, P. L., FENVES, A. Z., LOON, N. R., JAGANNATH, S., KUHN, J. A., DRATCH, A. D., & D'AGATI, V. D. (2001) · Journal of the American Society of Nephrology · doi:10.1681/asn.v1261164 · Cited by 466
Giuliani, N., Bataille, R., Mancini, C., Lazzaretti, M., & Barillé, S. (2001) · Blood · doi:10.1182/blood.v98.13.3527 · Cited by 415
Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma
Lahtinen, R., Laakso, M., Palva, I., Elomaa, I., & Virkkunen, P. (1992) · The Lancet · doi:10.1016/0140-6736(92)93075-x · Cited by 385
American Society of Clinical Oncology Guideline on the Role of Bisphosphonates in Breast Cancer
Hillner, B. E., Ingle, J. N., Berenson, J. R., Janjan, N. A., Albain, K. S., Lipton, A., Yee, G., Biermann, J. S., Chlebowski, R. T., Pfister, D. G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.6.1378 · Cited by 383
Self-citationOsteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma
Croucher, P. I. (2001) · Blood · doi:10.1182/blood.v98.13.3534 · Cited by 377
Current use of bisphosphonates in oncology. International Bone and Cancer Study Group.
Body, J. J., Bartl, R., Burckhardt, P., Delmas, P. D., Diel, I. J., Fleisch, H., Kanis, J. A., Kyle, R. A., Mundy, G. R., Paterson, A. H., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.12.3890 · Cited by 359
Self-citationA randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma
McCloskey, MacLennan, Drayson, Chapman, Dunn, Kanis, & Adults, F. T. M. W. P. O. L. I. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00567.x · Cited by 314
Studies of the oral bioavailability of alendronate*
Gertz, B. J., Holland, S. D., Kline, W. F., Matuszewski, B. K., Freeman, A., Quan, H., Lasseter, K. C., Mucklow, J. C., & Porras, A. G. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90245-7 · Cited by 262
Rules of Evidence and Clinical Recommendations on the Use of Antithrombotic Agents
Cook, D. J., Guyatt, G. H., Laupacis, A., & Sackett, D. L. (1992) · Chest · doi:10.1378/chest.102.4_supplement.305s · Cited by 217
Strontium 89 Therapy for the Palliation of Pain Due to Osseous Metastases
Robinson, R. G. (1995) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1995.03530050068035 · Cited by 199
Miller, P. D., Brown, J. P., Siris, E. S., Hoseyni, M. S., Axelrod, D. W., & Bekker, P. J. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00062-5 · Cited by 192
Ravn, P., Bidstrup, M., Wasnich, R. D., Davis, J. W., McClung, M. R., Balske, A., Coupland, C., Sahota, O., Kaur, A., Daley, M., et al. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-12-199912210-00005 · Cited by 186
McCloskey, E. V., Dunn, J. A., Kanis, J. A., MacLennan, I. C. M., Drayson, M. T., & the Medical Research Council Working Party on Leukaemia in Adults (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.02851.x · Cited by 181
Effect of daily etidronate on the osteolysis of multiple myeloma.
Belch, A. R., Bergsagel, D. E., Wilson, K., O'Reilly, S., Wilson, J., Sutton, D., Pater, J., Johnston, D., & Zee, B. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.8.1397 · Cited by 178
Menssen, H. D., Sakalová, A., Fontana, A., Herrmann, Z., Boewer, C., Facon, T., Lichinitser, M. R., Singer, C. R. J., Euller-Ziegler, L., Wetterwald, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.02.032 · Cited by 159
Localized and indolent myeloma
Alexanian, R. (1980) · Blood · doi:10.1182/blood.v56.3.521.521 · Cited by 141
Markers of bone resorption in patients treated with pamidronate
Lipton, A., Demers, L., Curley, E., Chinchilli, V. M., Gaydos, L. J., Hortobágyi, G. N., Theriault, R. L., Clemens, D., Costa, L., Seaman, J. J., et al. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00277-9 · Cited by 139
Self-citationDelmas, P. D., CHARHON, S. A., Chapuy, M. C., Vignon, E. P., Briançon, D., Edouard, C. M., & Meunier, P. J. (1982) · Metabolic Bone Disease and Related Research · doi:10.1016/0221-8747(82)90013-3 · Cited by 124
Bataille, R., Chappard, D., & Baslé, M. F. (1996) · Blood · doi:10.1182/blood.v87.11.4762.bloodjournal87114762 · Cited by 122
Monitoring individual response to hormone replacement therapy with bone markers
Delmas, P. D., Hardy, P., Garnero, P., & Dain, M. (2000) · Bone · doi:10.1016/s8756-3282(00)00271-4 · Cited by 121
Bloomfield, D. J. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.3.1218 · Cited by 120
Vinholes, J., Coleman, R. E., & Eastell, R. (1996) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(96)90021-3 · Cited by 117
Brincker, H., Westin, J., Abildgaard, N., Gimsing, P., Turesson, I., Hedenus, M., Ford, J., & Kandra, A. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00695.x · Cited by 114
Bisphosphonates and breast carcinoma
Lipton, A. (1997) · Cancer · Cited by 99
Self-citationRespiratory Diseases from Hard Metal or Cobalt Exposure
Demedts, M., & Ceuppens, J. L. (1989) · CHEST Journal · doi:10.1378/chest.95.1.2 · Cited by 99
ROSE, C., & Kagan, A. R. (1998) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(97)00952-8 · Cited by 89
BONE DISEASE IN MULTIPLE MYELOMA
Croucher, P. I., & Apperley, J. F. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.01082.x · Cited by 88
Coukell, A. J., & Markham, A. (1998) · Drugs & Aging · doi:10.2165/00002512-199812020-00007 · Cited by 82
Castel, L. D., Bajwa, K., Markle, J. P., Timbie, J. W., Zacker, C., & Schulman, K. A. (2001) · Supportive Care in Cancer · doi:10.1007/s005200100249 · Cited by 72
Terpos, E., Palermos, J., Tsionos, K., Anargyrou, K., Viniou, N. A., Papasavas, P., Meletis, J., & Yataganas, X. (2000) · European Journal Of Haematology · doi:10.1034/j.1600-0609.2000.065005331.x · Cited by 69
Bisphosphonates in the Treatment of Malignant Bone Disease
Berenson, J. R., & Lipton, A. (1999) · Annual Review of Medicine · doi:10.1146/annurev.med.50.1.237 · Cited by 65
Self-citationBisphosphonates and breast carcinoma
Lipton, A. (1997) · Cancer · Cited by 63
Self-citationHeim, M., Clemens, M. R., Queißer, W., Pecherstorfer, M., Boewer, C., Herold, M. J., Franke, A., Herrmann, Z., Loose, R., & Edler, L. (2009) · Onkologie · doi:10.1159/000218633 · Cited by 52
Pamidronate treatment in patients with malignant osteolytic bone disease and pain
Koeberle, D., Bacchus, L., Thuerlimann, B., & Senn, H.-J. (1999) · Supportive Care in Cancer · doi:10.1007/s005200050218 · Cited by 40
Daragon, A., Humez, C., Michot, C., Loët, X. L., Grosbois, B., Pouyol, F., EULLER-ZIEGLER, L., Azaïs, I., Jf, B., & Ménard, J.-F. (1993) · PubMed · Cited by 38
Body, J. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(97)10136-8 · Cited by 29
Counting Recurrent Events in Cancer Research
Glynn, R. J., & Buring, J. E. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.7.488 · Cited by 19
Berenson (2001) · doi:10.1002/1097-0142(20010401)91:7<1191::aid-cncr1119>3.0.co;2-0
Cited by
Ruggiero, S. L., Dodson, T. B., Fantasia, J., Goodday, R., Aghaloo, T., Mehrotra, B., & O'Ryan, F. (2014) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2014.04.031 · Cited by 2,905
Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases
Ruggiero, S. L., Mehrotra, B., Rosenberg, T. J., & Engroff, S. L. (2004) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2004.02.004 · Cited by 2,057
Tomblyn, M., Chiller, T., Einsele, H., Gress, R., Sepkowitz, K., Storek, J., Wingard, J. R., Young, J.-A. H., & Boeckh, M. A. (2009) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2009.06.019 · Cited by 1,797
Khosla, S., Burr, D., Cauley, J., Dempster, D. W., Ebeling, P. R., Felsenberg, D., Gagel, R. F., Gilsanz, V., Guise, T., Koka, S., et al. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.0707onj · Cited by 1,650
Bisphosphonates: Mechanism of action and role in clinical practice
Drake, M. T., Clarke, B. L., & Khosla, S. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.9.1032 · Cited by 1,644
Metadata
- Authors
- Berenson, J. R., Hillner, B. E., Kyle, R. A., Anderson, K., Lipton, A., Yee, G. C., & Biermann, J. S.
- Venue
- Journal of Clinical Oncology
- Published
- 2002-09-01
- Volume
- 20
- Issue
- 17
- Pages
- 3719-3736
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2141521877
- Cited by
- 542
- References
- 53
- FWCI
- 13.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.